NEW YORK (GenomeWeb) – Vermillion reported after the close of the market on Monday a 47 percent decline in first quarter revenues

For the three months ended March 31, the Austin, Texas-based cancer diagnostics firm said that total revenues fell to $505,000 from $951,000 in the year-ago quarter.

Product revenues were $505,000, down from $635,000 in Q1 2015. As Vermillion noted, product revenue in Q1 2015 included the one-time recognition of $163,000 in deferred product revenue upon the signing of its commercial agreement with Quest Diagnostics in March 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.